Product logins

Find logins to all Clarivate products below.


ANALYST CALL: Coming to America: Sandoz Files the First Biosimilar in the United States

Outline

• Sandoz’s biosimilar filgrastim development program

• Zarzio’s European performance

• U.S. oncologists’ expected uptake of biosimilar filgrastim

• U.S. payers’ price expectations and strategy to drive uptake

• Competitive landscape for biosimilars in the United States

• Potential differentiation strategies

• Next milestones for the U.S. biosimilar market

• Q&A

Related Market Assessment Reports

Report
Biosimilars – Forecast – Endocrinology
In 2024, sales of branded biologics for endocrinology indications (insulins and antiresorptive analogues) exceeded $22 billion in the major pharmaceutical markets under study (United States, EU5,…
Report
Biosimilars – Forecast – Immunology
In 2024, sales of branded biologics in immunology exceeded $65 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Sales of biosimilars in the major market in…
Report
Biosimilars – Forecast – Oncology
In 2024, sales of branded MAb biologics in oncology exceeded $48 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled $5.9 billion…
Report
Biosimilars – Forecast – Forecast Methodology and General Market Assumptions
In 2024, sales of branded biologics for oncology (except G-CSFs), immunology, endocrinology, ophthalmology, neurology, osteoporosis, and respiratory indications exceeded $160 billion in the major…
Report
Biosimilars – Forecast – Neurology
In 2024, sales of branded MAb biologics in neurology exceeded $12 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2024-2034 forecast period, the…